Bone Biologics Corporation
BBLG
$0.55
-$0.01-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.73% | 39.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.37% | 9.82% | |||
| Operating Income | -0.37% | -9.82% | |||
| Income Before Tax | -1.01% | -11.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.01% | -11.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.01% | -11.89% | |||
| EBIT | -0.37% | -9.82% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -0.91% | -12.32% | |||
| Normalized Basic EPS | -0.90% | -12.34% | |||
| EPS Diluted | -0.91% | -12.32% | |||
| Normalized Diluted EPS | -0.90% | -12.34% | |||
| Average Basic Shares Outstanding | 0.08% | -0.38% | |||
| Average Diluted Shares Outstanding | 0.08% | -0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||